metformin has been researched along with docetaxel anhydrous in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 15 (75.00) | 24.3611 |
| 2020's | 5 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kalamida, D; Koukourakis, MI; Mitrakas, AG | 1 |
| Kaddis, N; Saif, MW | 1 |
| Bansal, N; Bertino, JR; DiPaola, RS; Mishra, PJ; Stein, M | 1 |
| Bahl, A; Biernacka, KM; Gillatt, D; Holly, JM; Perks, CM; Persad, RA | 1 |
| Klotz, LH; Mayer, MJ; Venkateswaran, V | 2 |
| Preston, MA | 1 |
| Spratt, D | 1 |
| Abdallah, K; Hamilton, RJ; Joshua, AM; Khoja, L; Pintilie, M; Pitcher, B | 1 |
| Ozgur, BC | 1 |
| Abdel-Rahman, O | 1 |
| Fatehi-Agdam, M; Jeddi, F; Najafzadeh, N; Panahizadeh, R; Vatankhah, MA | 1 |
| Goebel, S; Hoelzer, D; Leovsky, C; Meyer, FB; Spangel, SB; Thierbach, R | 1 |
| Besson, D; Borchiellini, D; Bost, F; Cheli, S; Deville, JL; El Kouri, C; Ferrero, JM; Guillot, A; Hilgers, W; Hoch, B; Milano, G; Paoli, JB; Priou, F; Pujalte Martin, M; Schiappa, R; Tanti, JF; Thamphya, B | 1 |
| Farhoudi, L; Jaafari, MR; Kharrazi, S; Mashreghi, M; Mehrabian, A; Mirzavi, F; Rezayat, SM; Sadri, K; Vakili-Ghartavol, R | 1 |
| Catapano, J; Czyż, J; Kędracka-Krok, S; Luty, M; Madeja, Z; Piwowarczyk, K; Pudełek, M; Siedlar, M; Wróbel, T | 1 |
1 review(s) available for metformin and docetaxel anhydrous
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for metformin and docetaxel anhydrous
| Article | Year |
|---|---|
Impact of Diabetes on the Outcomes of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel: A Pooled Analysis of Three Phase III Studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus; Docetaxel; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2019 |
TAXOMET: A French Prospective Multicentric Randomized Phase II Study of Docetaxel Plus Metformin Versus Docetaxel Plus Placebo in Metastatic Castration-Resistant Prostate Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Metformin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Retrospective Studies; Treatment Outcome | 2021 |
17 other study(ies) available for metformin and docetaxel anhydrous
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
Topics: Amiodarone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Male; Metformin; Mitochondria; Prostatic Neoplasms; Radiation Tolerance; Taxoids | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Docetaxel; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; Male; Metformin; Neoplasm Invasiveness; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Taxoids; Triazoles; Up-Regulation | 2015 |
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 2; Male; Metformin; Prostatic Neoplasms; Protein Serine-Threonine Kinases; RNA, Small Interfering; Taxoids | 2017 |
The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Docetaxel; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2017 |
Editorial Comment.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant | 2017 |
Editorial Comment.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant | 2017 |
Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclooxygenase 2 Inhibitors; Disease Progression; Docetaxel; Heparin, Low-Molecular-Weight; Humans; Male; Metformin; Models, Theoretical; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Taxoids; Treatment Outcome; Warfarin | 2017 |
Evaluating Metformin as a Potential Chemosensitizing Agent when Combined with Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Cells.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Metformin; Phosphorylation; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Re: The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer: M. J. Mayer, L. H. Klotz and V. Venkateswaran J Urol 2017;197:1068-1075.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
Reply by Authors.
Topics: Diabetes Mellitus; Docetaxel; Humans; Male; Metformin; Prostatic Neoplasms, Castration-Resistant | 2018 |
Efficacy of Metformin and Chemotherapeutic Agents on the Inhibition of Colony Formation and Shh/Gli1 Pathway: Metformin/Docetaxel Versus Metformin/5-Fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Metformin; Signal Transduction; Stomach Neoplasms; Tumor Stem Cell Assay; Zinc Finger Protein GLI1 | 2021 |
Metformin alters therapeutic effects in the BALB/c tumor therapy model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BALB 3T3 Cells; Carcinogens; Cell Survival; Cell Transformation, Neoplastic; Culture Media; Docetaxel; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Fluorouracil; Glucose; Humans; Metformin; Methylcholanthrene; Mice; Mitomycin; Neoplasms | 2021 |
Docetaxel in combination with metformin enhances antitumour efficacy in metastatic breast carcinoma models: a promising cancer targeting based on PEGylated liposomes.
Topics: Ammonium Sulfate; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Liposomes; Metformin; Mice; Mice, Inbred BALB C; Neoplasms; Phosphates; Polyethylene Glycols; Tissue Distribution | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Metformin; Prostatic Neoplasms; Stress, Physiological; Taxoids | 2022 |